Therapies for Lysosomal Storage Diseases

Emery and Rimoin's Principles and Practice of Medical Genetics

Volumn , Issue , 2013, Pages 1-30

  Desnick, Robert J ^a   Schuchman, Edward H ^a   Astrin, Kenneth H ^b   Cheng, Seng H ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK COLLEGE OF PODIATRIC MEDICINE   (United States)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882789018     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-383834-6.00036-7     Document Type: Chapter

References (198)

1. R.J. Desnick and E.H. Schuchman (2002) Enzyme Replacement and Enhancement Therapies: Lessons from Lysosomal Disorders. Nat. Rev. Genet. 3 954.
2. N.M. Ellinwood, C.H. Vite and M.E. Haskins (2004) Gene Therapy for Lysosomal Storage Diseases: The Lessons and Promise of Animal Models. J. Gene Med. 6 481.
3. C.M. Eng, N. Guffon, W.R. Wilcox, et al. (2001) Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry’s Disease. N. Engl. J. Med. 345 9.
4. Y. Eto, J.S. Shen, X.L. Meng, et al. (2004) Treatment of Lysosomal Storage Disorders: Cell Therapy and Gene Therapy. J. Inherit. Metab. Dis. 27 411.
5. G.A. Grabowski and R.J. Hopkin (2003) Enzyme Therapy for Lysosomal Storage Disease: Principles, Practice, and Prospects. Annu. Rev. Genomics Hum. Genet. 4 403.
6. R. Schiffmann and R.O. Brady (2002) New Prospects for the Treatment of Lysosomal Storage Diseases. Drugs 62 733.
7. E.P. Treacy, D. Valle, C.R. Scriver (2001) Treatment of Genetic Disease. C.R. Scriver, A.L. Beaudet, W.S. Sly, et al., (Eds) The Metabolic and Molecular Bases of Inherited Diseases New York: McGraw-Hill 175.
8. F.E. Cohen and J.W. Kelly (2003) Therapeutic Approaches to Protein-Misfolding Diseases. Nature 426 905.
9. M. Cantz and H. Kresse (1974) Sandhoff Disease: Defective Glycosaminoglycan Catabolism in Cultured Fibroblasts and Its Correction by Beta-N-Acetylhexosaminidase. Eur. J. Biochem. 47 581.
10. J.S. O’Brien, A.L. Miller, A.W. Loverde, et al. (1973) Sanfilippo Disease Type B: Enzyme Replacement and Metabolic Correction in Cultured Fibroblasts. Science 181 753.
11. M.T. Porter, A.L. Fluharty and H. Kihara (1971) Correction of Abnormal Cerebroside Sulfate Metabolism in Cultured Metachromatic Leukodystrophy Fibroblasts. Science 172 1263.
12. S. Kornfeld (1990) Lysosomal Enzyme Targeting. Biochem. Soc. Trans. 18 367.
13. D.D. Sabatini, M.B. Adesnik (2001) The Biogenesis of Membranes and Organelles. C.R. Scriver, A.L. Beaudet, W.S. Sly, et al., (Eds) The Metabolic and Molecular Bases of Inherited Diseases New York: McGraw-Hill 475.
14. N.W. Barton, R.O. Brady, J.M. Dambrosia, et al. (1991) Replacement Therapy for Inherited Enzyme Deficiency—Macrophage-Targeted Glucocerebrosidase for Gaucher’s Disease. N. Engl. J. Med. 324 1464.
15. R.O. Brady and N.W. Barton (1991) Enzyme Replacement Therapy for Type I Gaucher Disease. R.J. Desnick (Eds) Treatment of Genetic Diseases New York: Churchill Livingstone 153.
16. B.E. Smid, J.M.F.G. Aerts, R.G. Boot, et al. (2010) Pharmacological Small Molecules for the Treatment of Lysosomal Storage Disorders. Expert Opin. Investig. Drugs 19 1367.
17. N. Radin (1996) Treatment of Gaucher Disease with an Enzyme Inhibitor. Glycoconj. J. 13 153.
18. F.M. Platt and M. Jeyakumar (2008) Substrate Reduction Therapy. Acta Paediatr. 97 88.
19. F.M. Platt, G.R. Neises, G. Reinkensmeier, et al. (1997) Prevention of Lysosomal Storage in Tay–Sachs Mice Treated with N-Butyldeoxynojirimycin. Science 276 428.
20. R.R. Vunnam and N.S. Radin (1980) Analogs of Ceramide that Inhibit Glucocerebroside Synthetase in Mouse Brain. Chem. Phys. Lipids 26 265.
21. T. Cox, R. Lachmann, C. Hollack, et al. (2000) Novel Oral Treatment of Gaucher’s Disease with N-Butyldeoxynojirimycin (OCT 918) to Decrease Substrate Biosynthesis. Lancet 355 1481.
22. M.C. Patterson, D. Vecchio, H. Prady, L. Abel and J.E. Wraith (2007) Miglustat for Treatment of Niemann–Pick C Disease: A Randomised Controlled Study. Lancet Neurol. 6 765.
23. D.H. Perlmutter (2002) Chemical Chaperones: A Pharmacological Strategy for Disorders of Protein Folding and Trafficking. Pediatr. Res. 52 832.
24. R.J. Desnick (2004) Enzyme Replacement and Enhancement Therapies for Lysosomal Diseases. J. Inherit. Metab. Dis. 27 385.
25. A. Ulloa-Aguirre, J.A. Janovick, S.P. Brothers, et al. (2004) Pharmacologic Rescue of Conformationally-Defective Proteins: Implications for the Treatment of Human Disease. Traffic 5 821.
26. R. Hampton (2002) ER-Associated Degradation in Protein Quality Control and Cellular Regulation. Curr. Opin. Cell Biol. 14 476.
27. B. Meusser, C. Hirsch, E. Jarosch, et al. (2005) ERAD: The Long Road to Destruction. Nat. Cell Biol. 7 766.
28. S.H. Cheng and A.E. Smith (2003) Gene Therapy Progress and Prospects: Gene Therapy of Lysosomal Storage Disorders. Gene Ther. 10 1275.
29. A. Biffi and L. Naldini (2005) Gene Therapy of Storage Disorders by Retroviral and Lentiviral Vectors. Hum. Gene Ther. 16 1133.
30. M.S. Sands and B.L. Davidson (2006) Gene Therapy for Lysosomal Storage Diseases. Mol. Ther. 13 839.
31. R.J. Desnick, R.W. Bernlohr and W. Krivit (Eds) (1973) Enzyme Therapy in Genetic Diseases. Birth Defects Orig. Art. Ser IX IX (2)
32. R.J. Desnick, S.R. Thorpe and M.B. Fiddler (1976) Toward Enzyme Therapy for Lysosomal Storage Diseases. Physiol. Rev 56 57.
33. J.M. Tager, G.J.M. Hooghvinkel and W.T. Daems (Eds) (1974) Enzyme Therapy in Lysosomal Storage Diseases Amsterdam: North-Holland Publishing Company
34. R.J. Desnick (Eds) (1980) Enzyme Therapy in Genetic Diseases: 2 New York: Alan R Liss
35. W.G. Johnson, R.J. Desnick, D.M. Long, et al. (1973) Intravenous Injection of Purified Hexosaminidase A into a Patient with Tay–Sachs Disease. Birth Defects Orig. Art. Ser. IX 120.
36. R.O. Brady, P.G. Pentchev, A.E. Gal, et al. (1974) Replacement Therapy for Inherited Enzyme Deficiency: Use of Purified Glucocerebrosidase in Gaucher’s Disease. N. Engl. J. Med. 291 989.
37. T.W. Doebber, M.S. Wu, R.L. Bugianesi, et al. (1982) Enhanced Macrophage Uptake of Synthetically Glycosylated Human Placental Beta-Glucocerebrosidase. J. Biol. Chem. 257 2193.
38. R.O. Brady, J.A. Barranger, A.E. Gal, et al. (1980) Status of Enzyme Replacement Therapy for Gaucher Disease. R.J. Desnick (Eds) Enzyme Therapy in Genetic Disease: 2 New York: Alan R Liss 361.
39. N.W. Barton, F.S. Furbish, G.J. Murray, et al. (1990) Therapeutic Response to Intravenous Infusions of Glucocerebrosidase in a Patient with Gaucher Disease. Proc. Natl. Acad. Sci. U.S.A. 87 1913.
40. G.A. Grabowski, N.W. Barton, G. Pastores, et al. (1995) Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant Sources. Ann. Intern. Med. 122 33.
41. G.A. Grabowski, N. Leslie and R. Wenstrup (1998) Enzyme Therapy for Gaucher Disease: The First 5 Years. Blood Rev. 12 115.
42. N.J. Weinreb, J. Charrow, H.C. Andersson, et al. (2002) Effectiveness of Enzyme Replacement Therapy in 1028 Patients with Type 1 Gaucher Disease after 2 to 5 Years of Treatment: A Report from the Gaucher Registry. Am. J. Med. 113 112.
43. B. Brumshtein, P. Salinas, B. Peterson, et al. (2009) Characterization of Gene-Activated Acid b-Glucosidase: Crystal Structure, Glycan Composition, and Internalization into Macrophages. Glycobiology 20 24.
44. D. Aviezer, E. Brill-Almon, Y. Shaaltiel, et al. (2009) A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme— A Preclinical and Phase I Investigation. PLoS ONE 4 e4792.
45. Y.-H. Xu, Y. Sun, S. Barnes, et al. (2010) Comparative Therapeutic Effects of Velaglucerase Alfa and Imiglucerase in a Gaucher Disease Mouse Model. PLoS ONE 5 e10750.
46. A. Zimran, G. Altarescu, M. Philips, et al. (2010) Phase 1/2 and Extension Study of Velaglucerase Alfa Replacement Therapy in Adults with Type 1 Gaucher Disease: 48-Month Experience. Blood 115 4651.
47. Y.A. Ioannou, D.F. Bishop and R.J. Desnick (1992) Overexpression of Human α-Galactosidase A Results in Its Intracellular Aggregation, Crystallization in Lysosomes and Selective Secretion. J. Cell. Biol. 119 1137.
48. Y.A. Ioannou, K.M. Zeidner, R.E. Gordon, et al. (2001) Fabry Disease: Preclinical Studies Demonstrate the Effectiveness of α-Galactosidase A Replacement in Enzyme-Deficient Mice. Am. J. Hum. Genet. 68 14.
49. S.R. Miranda, X. He, C.M. Simonaro, et al. (2000) Infusion of Recombinant Human Acid Sphingomyelinase into Niemann–Pick Disease Mice Leads to Visceral, but Not Neurological, Correction of the Pathophysiology. FASEB J. 14 1988.
50. G.M. Pastores, A.R. Sibille and G.A. Grabowski (1993) Enzyme Therapy in Gaucher Disease Type 1: Dosage Efficacy and Adverse Effects in 33 Patients Treated for 6 to 24 Months. Blood 82 408.
51. S.M. Richards, T.A. Olson and J.M. McPherson (1993) Antibody Response in Patients with Gaucher Disease after Repeated Infusion with Macrophage-Targeted Glucocerebrosidase. Blood 82 1402.
52. M. Rosenberg, W. Kingma, M.A. Fitzpatrick, et al. (1999) Immunosurveillance of Alglucerase Enzyme Therapy for Gaucher Patients: Induction of Humoral Tolerance in Seroconverted Patients after Repeat Administration. Blood 93 2081.
53. R. Schiffmann, J.B. Kopp, H.A. Austin 3rd, et al. (2001) Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial. JAMA 285 2743.
54. J.E. Wraith (2005) The First 5 Years of Clinical Experience with Laronidase Enzyme Replacement Therapy for Mucopolysaccharidosis I. Expert Opin. Pharmacother 6 489.
55. J.E. Wraith, L.A. Clarke, M. Beck, et al. (2004) Enzyme Replacement Therapy for Mucopolysaccharidosis I: A Randomized, Double-Blinded, Placebo-Controlled, Multinational Study of Recombinant Human Alpha-L-Iduronidase (Laronidase). J. Pediatr 144 581.
56. P. Harmatz, C.B. Whitley, L. Waber, et al. (2004) Enzyme Replacement Therapy in Mucopolysaccharidosis VI (Maroteaux–Lamy Syndrome). J. Pediatr. 144 574.
57. L. Klinge, V. Straub, U. Neudorf, et al. (2005) Safety and Efficacy of Recombinant Acid Alpha-Glucosidase (rhGAA) in Patients with Classical Infantile Pompe Disease: Results of a Phase II Clinical Trial. Neuromuscul. Disord. 15 24.
58. A.T. Van der Ploegh, P.R. Clemen, D. Corzo, et al. (2010) A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe’s Disease. N. Engl. J. Med. 362 1396.
59. L.P. Winkel, J.M. Van den Hout, J.H. Kamphoven, et al. (2004) Enzyme Replacement Therapy in Late-Onset Pompe’s Disease: A Three-Year Follow-Up. Ann. Neurol 55 495.
60. J. Muenzer, M. Beck, C.M. Eng, et al. (2011) Long-Term, Open-Labeled Extension Study of Idursulfase in the Treatment of Hunter Syndrome. Genet. Med. 13 95.
61. J. Muenzer, M. Calikoglu, D. Towle, et al. (2003) The One Year Experience of Enzyme Replacement Therapy for Mucopolysaccharidosis II (Hunter Syndrome). Am. J. Hum. Genet. 73 623.
62. E.J. Bonten, J.N. Toy, L. Mann, et al. (2002) Effective Enzyme Replacement Therapy of Murine Galactosialidosis Using Insect Cell-Expressed PPCA and Neuraminidase. Am. J. Hum. Genet. 71 420.
63. H. Du, S. Schiavi, M. Levine, et al. (2001) Enzyme Therapy for Lysosomal Acid Lipase Deficiency in the Mouse. Hum. Mol. Genet. 10 1639.
64. M.S. Sands, C.A. Vogler, K.K. Ohlemiller, et al. (2001) Biodistribution, Kinetics, and Efficacy of Highly Phosphorylated and Non-Phosphorylated Beta-Glucuronidase in the Murine Model of Mucopolysaccharidosis VII. J. Biol. Chem. 276 43160.
65. C. Vogler, B. Levy, N.J. Galvin, et al. (1999) Enzyme Replacement in Murine Mucopolysaccharidosis Type VII: Neuronal and Glial Response to Beta-Glucuronidase Requires Early Initiation of Enzyme Replacement Therapy. Pediatr. Res. 45 342.
66. C. Vogler, B. Levy, J.H. Grubb, et al. (2005) Overcoming the Blood–Brain Barrier with High-Dose Enzyme Replacement Therapy in Murine Mucopolysaccharidosis VII. Proc. Natl. Acad. Sci. U.S.A. 102 14777.
67. R.J. Desnick, Y.A. Ioannou, C.M. Eng (2001) α-Galactosidase A Deficiency: Fabry Disease. C.R. Scriver, A.L. Beaudet, W.S. Sly, et al., (Eds) The Metabolic and Molecular Bases of Inherited Diseases New York: McGraw-Hill 3733.
68. R.J. Desnick, K.J. Dean, G. Grabowski, et al. (1979) Enzyme Therpy in Fabry Disease: Differential In Vivo Plasma Clearance and Metabolic Effectiveness of Plasma and Splenic α-Galactosidase A Isozymes. Proc. Natl. Acad. Sci. U.S.A. 76 5326.
69. R.O. Brady, J.F. Tallman, W.G. Johnson, et al. (1973) Replacement Therapy for Inherited Enzyme Deficiency: Use of Purified Ceramide Trihexosidase in Fabry’s Disease. N. Engl. J. Med. 289 9.
70. C.A. Mapes, R.L. Anderson, R.J. Desnick, et al. (1970) Enzyme Replacement as a Possible Therapy for Fabry’s Disease. Science 169 987.
71. D.F. Bishop, D.H. Calhoun, H.S. Bernstein, et al. (1986) Human α-Galactosidase A: Nucleotide Sequence of a CDNA Clone Encoding the Mature Enzyme. Proc. Natl. Acad. Sci. U.S.A. 83 4859.
72. A.M. Wang, Y.A. Ioannou, K.M. Zeidner, et al. (1996) Generation of a Mouse Model with α-Galactosidase A Deficiency. Am. J. Hum. Genet. 59 A208.
73. A.G. Bijvoet, H. Van Hirtum, M.A. Kroos, et al. (1999) Human Acid α-Glucosidase from Rabbit Milk Has Therapeutic Effect in Mice with Glycogen Storage Disease Type II. Hum. Mol. Genet. 8 2145.
74. R.J. Desnick (2004) Enzyme Replacement Therapy for Fabry Disease: Lessons from Two Alpha-Galactosidase A Orphan Products and One FDA Approval. Expert Opin. Biol. Ther. 4 1167.
75. C.M. Eng, M. Banikazemi, R. Gordon, et al. (2001) A Phase 1/2 Clinical Trial of Enzyme Replacement in Fabry Disease: Pharmacokinetic, Substrate Clearance, and Safety Studies. Am. J. Hum. Genet. 68 711.
76. R. Schiffmann, G.J. Murray, D. Treco, et al. (2000) Infusion of Alpha-Galactosidase A Reduces Tissue Globotriaosylceramide Storage in Patients with Fabry Disease. Proc. Natl. Acad. Sci. U.S.A. 97 365.
77. W.R. Wilcox, M. Banikazemi, N. Guffon, et al. (2004) Long-Term Safety and Efficacy of Enzyme Replacement Therapy for Fabry Disease. Am. J. Hum. Genet. 75 65.
78. C.E. Hollak, S. van Weely, M.H. van Oers, et al. (1994) Marked Elevation of Plasma Chitotriosidase Activity: A Novel Hallmark of Gaucher Disease. J. Clin. Invest. 93 1288.
79. K.A. McEachern, J. Fung, S. Komarnitsky, et al. (2007) A Specific and Potent Inhibitor of Glucosylceramide Synthase for Substrate Inhibition Therapy of Gaucher Disease. Mol. Genet. Metab. 91 259.
80. K. Lee, X. Jin, K. Zhang, et al. (2003) A Biochemical and Pharmacological Comparison of Enzyme Replacement Therapies for the Glycolipid Storage Disorder Fabry Disease. Glycobiology 13 305.
81. H. Sakuraba, M. Murata-Ohsawa, I. Kawashima, et al. (2006) Comparison of the Effects of Agalsidase Alfa and Agalsidase Beta on Cultured Human Fabry Fibroblasts and Fabry Mice. J. Hum. Genet. 51 180.
82. O. Lidove, M.L. West, G. Pintos-Morell, et al. (2010) Effects of Enzyme Replacement Therapy in Fabry Disease—A Comprehensive Review of the Medical Literature. Genet. Med. 12 668.
83. B.L. Thurberg, H. Rennke, R.B. Colvin, et al. (2002) Globotriaosylceramide Accumulation in the Fabry Kidney Is Cleared from Multiple Cell Types after Enzyme Replacement Therapy. Kidney Int. 62 1933.
84. G. De Schoenmakere, D. Chauveau and J.P. Grunfeld (2003) Enzyme Replacement Therapy in Anderson–Fabry’s Disease: Beneficial Clinical Effect on Vital Organ Function. Nephrol. Dial. Transplant. 18 33.
85. L. Spinelli, A. Pisani, M. Sabbatini, et al. (2004) Enzyme Replacement Therapy with Agalsidase Beta Improves Cardiac Involvement in Fabry’s Disease. Clin. Genet. 66 158.
86. S. Waldek (2003) PR Interval and the Response to Enzyme-Replacement Therapy for Fabry’s Disease. N. Engl. J. Med. 348 1186.
87. F. Weidemann, F. Breunig, M. Beer, et al. (2003) Improvement of Cardiac Function during Enzyme Replacement Therapy in Patients with Fabry Disease: A Prospective Strain Rate Imaging Study. Circulation 108 1299.
88. M. Banikazemi, T. Ullman and R.J. Desnick (2005) Gastrointestinal Manifestations of Fabry Disease: Clinical Response to Enzyme Replacement Therapy. Mol. Genet. Metab. 85 255.
89. M.J. Hilz, M. Brys, H. Marthol, et al. (2004) Enzyme Replacement Therapy Improves Function of C-, Adelta-, and Abeta-Nerve Fibers in Fabry Neuropathy. Neurology 62 1066.
90. N. Guffon and A. Fouilhoux (2004) Clinical Benefit in Fabry Patients Given Enzyme Replacement Therapy—A Case Series. J. Inherit. Metab. Dis. 27 221.
91. M. Kosch, H.G. Koch, J.P. Oliveira, et al. (2004) Enzyme Replacement Therapy Administered during Hemodialysis in Patients with Fabry Disease. Kidney Int. 66 1279.
92. A. Pisani, L. Spinelli, M. Sabbatini, et al. (2005) Enzyme Replacement Therapy in Fabry Disease Patients Undergoing Dialysis: Effects on Quality of Life and Organ Involvement. Am. J. Kidney Dis. 46 120.
93. R.J. Desnick, R. Brady, J. Barranger, et al. (2003) Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy. Ann. Intern. Med. 138 338.
94. E.D. Kakkis, M.F. McEntee, A. Schmidtchen, et al. (1996) Long-Term and High-Dose Trials of Enzyme Replacement Therapy in the Canine Model of Mucopolysaccharidosis I. Biochem. Mol. Med. 58 156.
95. R.M. Shull, E.D. Kakkis, M.F. McEntee, et al. (1994) Enzyme Replacement in a Canine Model of Hurler Syndrome. Proc. Natl. Acad. Sci. U.S.A. 91 12937.
96. E.D. Kakkis, J. Muenzer, G.E. Tiller, et al. (2001) Enzyme-Replacement Therapy in Mucopolysaccharidosis I. N. Engl. J. Med. 344 182.
97. L.A. Clarke, J.E. Wraith, M. Beck, et al. (2003) Aldurazyme (Iduronidase) Enzyme Replacement Therapy for MPS I: 48-Week Extension Data. Am. J. Hum. Genet. 73 623.
98. S. Byers, A.C. Crawley, L.K. Brumfield, et al. (2000) Enzyme Replacement Therapy in a Feline Model of MPS VI: Modification of Enzyme Structure and Dose Frequency. Pediatr. Res. 47 743.
99. P. Harmatz, D. Ketteridge, R. Giugliani, et al. (2005) Direct Comparison of Measures of Endurance, Mobility, and Joint Function during Enzyme-Replacement Therapy of Mucopolysaccharidosis VI (Maroteaux–Lamy Syndrome): Results after 48 Weeks in a Phase 2 Open-Label Clinical Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase. Pediatrics 115 e681.
100. P.S. Kishnani, D. Corzo, M. Nicolino, et al. (2007) Recombinant Human Acid α-Glucosidase; Major Clinical Benefits in Infantile-Onset Pompe Disease. Neurology 68 99.
101. J. Muenzer, M. Gucsavas-Calikoglu, S.E. McCandless, et al. (2007) A Phase I/II Clinical Trial of Enzyme Replacement Therapy in Mucopolysaccharidosis II (Hunter Syndrome). Mol. Genet. Metab. 90 329.
102. J. Muenzer, D. Towle, M. Calikoglu, et al. (2002) A Phase I/II Clinical Study Evaluating the Safety and Clinical Activity of Enzyme Replacement Therapy in Mucopolysaccharidosis II (Hunter Syndrome). Am. J. Hum. Genet. 71 582.
103. J. Muenzer, J.E. Wraith, M. Beck, et al. (2006) A Phase II/III Clinical Study of Enzyme Replacement Therapy with Idursulfase in Mucopolysaccharidosis II (Hunter Syndrome). Genet. Med. 8 465.
104. J.L. Van Hove, H.W. Yang, J.Y. Wu, et al. (1996) High-Level Production of Recombinant Human Lysosomal Acid Alpha-Glucosidase in Chinese Hamster Ovary Cells Which Targets to Heart Muscle and Corrects Glycogen Accumulation in Fibroblasts from Patients with Pompe Disease. Proc. Natl. Acad. Sci. U.S.A. 93 65.
105. T. Kikuchi, H.W. Yang, M. Pennybacker, et al. (1998) Clinical and Metabolic Correction of Pompe Disease by Enzyme Therapy in Acid Maltase-Deficient Quail. J. Clin. Invest. 101 827.
106. J. Van den Hout, J. Kamphoven, L. Winkel, et al. (2004) Long-Term Intravenous Treatment of Pompe Disease with Recombinant Human α-Glucosidase from Milk. Pediatrics 113 e448.
107. H. Van den Hout, A.J. Reuser, A.G. Vulto, et al. (2000) Recombinant Human Alpha-Glucosidase from Rabbit Milk in Pompe Patients. Lancet 356 397.
108. A. Amalfitano, A.R. Bengur, R.P. Morse, et al. (2001) Recombinant Human Acid Alpha-Glucosidase Enzyme Therapy for Infantile Glycogen Storage Disease Type II: Results of a Phase I/II Clinical Trial. Genet. Med. 3 132.
109. L. Klinge, V. Straub, U. Neudorf, et al. (2005) Enzyme Replacement Therapy in Classical Infantile Pompe Disease: Results of a Ten-Month Follow-Up Study. Neuropediatrics 36 6.
110. P. Kishnani, T. Voit, M. Nicolino, et al. (2002) Treatment of Classical Infantile Pompe Disease (CIPD) with Recombinant Human Acid Alpha Glucosidase (rhGAA): Preliminary 6 Month Data from a Phase 2 Study. Am. J. Hum. Genet. 71 582.
111. P.S. Kishnani, M. Nicolino, T. Voit, et al. (2004) Enzyme Replacement Therapy (ERT) for Infantile Onset Pompe Disease: Long-Term Follow-Up Results. Genet. Med. 6 268.
112. M. Nicolino, B. Byrne, J.E. Wraith, et al. (2009) Clinical Outcomes after Long-Term Treatment with Alglucosidase Alfa in Infants and Children with Advanced Pompe Disease. Genet. Med. 11 210.
113. S. Strothotte, N. Strigl-Pill, B. Grunert, et al. (2010) Enzyme Replacement Therapy with Alglucosidase Alfa in 44 Patients with Late-Onset Glycogen Storage Disease Type 2: 12-Month Results of an Observational Clinical Trial. J. Neurol. 257 91.
114. E.H. Schuchman, R.J. Desnick (2001) Niemann–Pick Disease Types A and B: Acid Sphingomyelinase Deficiencies. C.R. Scriver, A.L. Beaudet, W.S. Sly, et al., (Eds) The Metabolic and Molecular Bases of Inherited Diseases New York: McGraw-Hill 3589.
115. X. He, S.R. Mira, X. Xiong, et al. (1999) Characterization of Human Acid Sphingomyelinase Purified from the Media of Overexpressing Chinese Hamster Ovary Cells. Biochim. Biophys. Acta 1432 251.
116. R.J. Stockert (1995) The Asialoglycoprotein Receptor: Relationships between Structure, Function, and Expression. Physiol. Rev. 75 591.
117. B. Aguilera, K. Ghauharali-van der Vlugt, M.T. Helmond, et al. (2003) Transglycosidase Activity of Chitotriosidase: Improved Enzymatic Assay for the Human Macrophage Chitinase. J. Biol. Chem. 278 40911.
118. J.W. Yewdell (2001) Not Such a Dismal Science: The Economics of Protein Synthesis, Folding, Degradation and Antigen Processing. Trends Cell Biol. 11 294.
119. G. Pastores and N.L. Barnett (2004) Substrate Reduction Therapy: Miglustat as a Remedy for Symptomatic Patients with Gaucher Disease Type I. Expert Opin. Investig. Drugs 12 273.
120. J. Marshall, K.M. Ashe, D. Bangari, et al. (2010) Substrate Reduction Augments the Efficacy of Enzyme Therapy in a Mouse Model of Fabry Disease. PLoS ONE 5 e15033.
121. R. Schiffmann, E.J. FitzGibbon, C. Harris, et al. (2008) Randomized, Controlled Trial of Miglustat in Gaucher’s Disease Type 3. Ann. Neurol 64 514.
122. A. Abe, N.S. Radin, J.A. Shayman, et al. (1995) Structural and Stereochemical Studies of Potent Inhibitors of Glucosylceramide Synthase and Tumor Cell Growth. J. Lipid Res. 36 611.
123. F.M. Platt, G.R. Neises, R.A. Dwek, et al. (1994) N-Butyldeoxynojirimycin Is a Novel Inhibitor of Glycolipid Biosynthesis. J. Biol. Chem. 269 8362.
124. M. Jeyakumar, T.D. Butters, M. Cortina-Borja, et al. (1999) Delayed Symptom Onset and Increased Life Expectancy in Sandhoff Disease Mice Treated with N-Butyldeoxynojirimycin. Proc. Natl. Acad. Sci. U.S.A. 96 6388.
125. T. Heare, N.J. Alp, D.A. Priestman, et al. (2007) Severe Endothelial Dysfunction in the Aorta of a Mouse Model of Fabry Disease; Partial Prevention by N-Butyldeoxynojirimycin Treatment. J. Inherit. Metab. Dis. 30 79.
126. E. Elliot-Smith, A.O. Speak, E. Lloyd-Evans, et al. (2008) Beneficial Effects of Substrate Reduction Therapy in a Mouse Model of GM1 Gangliosidosis. Mol. Genet. Metab. 94 204.
127. M. Zervas, K.L. Somers, M.A. Thrall and S.U. Walkley (2001) Critical Role for Glycosphingolipids in Niemann–Pick Disease Type C. Curr. Biol. 11 1283.
128. M. Fischl, L. Resnick, R. Coombs, et al. (1994) The Safety and Efficacy of Combination N-Butyl-Deoxynojirimycin (SC-48334) and Zidovudine in Patients with HIV-1 Infection and 200–500 CD4 cells/mm3. J. Acquir. Immune Defic. Syndr. 7 139.
129. J. Marshall, K.A. McEachern, W.L. Chuang, et al. (2010) Improved Management of Lysosomal Glucosylceramide Levels in a Mouse Model of Type 1 Gaucher Disease Using Enzyme and Substrate Reduction Therapy. J. Inherit. Metab. Dis. 33 281.
130. D. Elstein, C. Hollack, J. Aerts, et al. (2004) Sustained Therapeutic Effects of Oral Miglustat (Zavesca, N-Butyldeoxynojirimycin, OGT-918) in Type 1 Gaucher Disease. J. Inherit. Metab. Dis. 27 757.
131. G.M. Pastores, N.L. Barnett and E.H. Kolodny (2005) An Open-Label, Noncomparative Study of Miglustat in Type 1 Gaucher Disease: Efficacy and Tolerability Over 24 Months of Treatment. Clin. Ther. 27 1215.
132. R. Heitner, D. Elstein, J. Aerts, et al. (2002) Low Dose N-Butyldeoxynojirimycin (OGT 918) for Type 1 Gaucher Disease. Blood Cells Mol. Dis. 28 127.
133. D. Elstein, A. Dweck, D. Attias, et al. (2007) Oral Maintenance Clinical Trial with Miglustat for Type 1 Gaucher Disease: Switch from or Combination with Intravenous Enzyme Replacement. Blood 110 2296.
134. J.K. Amory, C.H. Muller, S.T. Page, et al. (2007) Miglustat Has No Apparent Effect on Spermatogenesis in Normal Men. Hum. Reprod. 22 702.
135. M.J. Peterschmitt, A. Burke, L. Blankstein, et al. (2011) Safety, Tolerability, and Pharmacokinetics of Eliglustat Tartrate (Genz-116238) after Single Doses, Multiple Doses, and Food in Healthy Volunteers. J. Clin. Pharmacol. 51 695.
136. E. Lukina, N. Watman, E.A. Arreguin, et al. (2010) A Phase 2 Study of Eliglustat Tartrate (Genz-112638), an Oral Substrate Reduction Therapy for Gaucher Disease Type 1. Blood 116 893.
137. E. Lukina, N. Watman, E.A. Arreguin, et al. (2010) Improvement in Hematological, Visceral, and Skeletal Manifestations of Gaucher Disease Type 1 with Oral Eliglustat Tartrate (Genz-112638) Treatment: 2-Year Results of a Phase 2 Study. Blood 116 4095.
138. A. Abe, S. Gregory, L. Lee, et al. (2000) Reduction of Globotriaosylceramide in Fabry Disease Mice by Substrate Deprivation. J. Clin. Invest. 105 1563.
139. T.M. Cox, F.M. Platt and J.M.F.G. Aerts (2007) Medicinal Use of Iminosugars. P. Compain, O.R. Martin (Eds) Iminosugars John Wiley and Sons Ltd 295.
140. A. Treiber, O. Morand and M. Clozel (2007) The Pharmacokinetics and Tissue Distribution of the Glucosylceramide Synthase Inhibitor Miglustat in the Rat. Xenobiotica 37 298.
141. J. Cox-Brinkman, M.J. van Breeman, B.T. van Maldegem, et al. (2008) Potential Efficacy of Enzyme Replacement and Substrate Reduction Therapy in Three Siblings with Gaucher Disease Type III. J. Inherit. Metab. Dis. 31 745.
142. G.H.B. Maegawa, B.L. Banwell, S. Blaser, et al. (2009) Substrate Reduction Therapy in Juvenile GM2 Gangliosidosis. Mol. Genet. Metab. 98 215.
143. B. Bembi, F. Marchetti, V.I. Guerci, et al. (2006) Substrate Reduction Therapy in the Infantile Form of Tay–Sachs Disease. Neurology 66 278.
144. J.E. Wraith, D. Vecchio, E. Jacklin, et al. (2010) Miglustat in Adult and Juvenile Patients with Niemann–Pick Disease Type C: Long-Term Data from a Clinical Trial. Mol. Genet. Metab. 99 351.
145. M.C. Patterson, D. Vecchio, E. Jacklin, et al. (2010) Long-Term Miglustat Therapy in Children with Niemann–Pick Disease Type C. J. Child Neurol. 25 300.
146. M. Pineda, M.S. Perez-Poyato, M. O’Callaghan, et al. (2010) Clinical Experience with Miglustat Therapy in Pediatric Patients with Niemann–Pick Disease Type C: A Case Series. Mol. Genet. Metab. 99 358.
147. J.Q. Fan (2003) A Contradictory Treatment for Lysosomal Storage Disorders: Inhibitors Enhance Mutant Enzyme Activity. Trends Pharmacol. Sci. 24 355.
148. J.Q. Fan, S. Ishii, N. Asano, et al. (1999) Accelerated Transport and Maturation of Lysosomal Alpha-Galactosidase A in Fabry Lymphoblasts by an Enzyme Inhibitor. Nat. Med. 5 112.
149. N. Asano, S. Ishii, H. Kizu, et al. (2000) In Vitro Inhibition and Intracellular Enhancement of Lysosomal α-Galactosidase A Activity in Fabry Lymphoblasts by 1-Deoxygalactonojirimycin and Its Derivatives. Eur. J. Biochem. 267 4179.
150. P. Alfonso, S. Pampin, J. Estrada, et al. (2005) Miglustat (NB-DNJ) Works as a Chaperone for Mutated Acid Beta-Glucosidase in Cells Transfected with Several Gaucher Disease Mutations. Blood Cells Mol. Dis. 35 268.
151. H. Lin, Y. Sugimoto, Y. Ohsaki, et al. (2004) N-Octyl-Beta-Valienamine Up-Regulates Activity of F213I Mutant Beta-Glucosidase in Cultured Cells: A Potential Chemical Chaperone Therapy for Gaucher Disease. Biochim. Biophys. Acta 1689 219.
152. J. Matsuda, O. Suzuki, A. Oshima, et al. (2003) Chemical Chaperone Therapy for Brain Pathology in GM1-Gangliosidosis. Proc. Natl. Acad. Sci. U.S.A. 100 15912.
153. A.R. Sawkar, W.C. Cheng, E. Beutler, et al. (2002) Chemical Chaperones Increase the Cellular Activity of N370S Beta-Glucosidase: A Therapeutic Strategy for Gaucher Disease. Proc. Natl. Acad. Sci. U.S.A. 99 15428.
154. M.B. Tropak, S.P. Reid, M. Guiral, et al. (2004) Pharmacological Enhancement of Beta-Hexosaminidase Activity in Fibroblasts from Adult Tay–Sachs and Sandhoff Patients. J. Biol. Chem. 279 13478.
155. A. Frustaci, C. Chimenti, R. Ricci, et al. (2001) Improvement in Cardiac Function in the Cardiac Variant of Fabry’s Disease with Galactose-Infusion Therapy. N. Engl. J. Med. 345 25.
156. C.B. Anfinsen and H.A. Scheraga (1975) Experimental and Theoretical Aspects of Protein Folding. Adv. Protein Chem. 29 205.
157. F.U. Hartl and M. Hayer-Hartl (2002) Molecular Chaperones in the Cytosol: From Nascent Chain to Folded Protein. Science 295 1852.
158. L. Ellgaard, M. Molinari and A. Helenius (1999) Setting the Standards: Quality Control in the Secretory Pathway. Science 286 1882.
159. S.W. Fewell, K.J. Travers, J.S. Weissman, et al. (2001) The Action of Molecular Chaperones in the Early Secretory Pathway. Annu. Rev. Genet. 35 149.
160. Y. Oda, N. Hosokawa, I. Wada, et al. (2003) EDEM as an Acceptor of Terminally Misfolded Glycoproteins Released from Calnexin. Science 299 1394.
161. M.F. Princiotta, D. Finzi, S.B. Qian, et al. (2003) Quantitating Protein Synthesis, Degradation, and Endogenous Antigen Processing. Immunity 18 343.
162. U. Schubert, L.C. Anton, J. Gibbs, et al. (2000) Rapid Degradation of a Large Fraction of Newly Synthesized Proteins by Proteasomes. Nature 404 770.
163. A. Horwich (2002) Protein Aggregation in Disease: A Role for Folding Intermediates Forming Specific Multimeric Interactions. J. Clin. Invest. 110 1221.
164. N. Pedemonte, G.L. Lukacs, K. Du, et al. (2005) Small-Molecule Correctors of Defective DeltaF508-CFTR Cellular Processing Identified by High-Throughput Screening. J. Clin. Invest. 115 2564.
165. A.R. Sawkar, S.L. Adamski-Werner, W.C. Cheng, et al. (2005) Gaucher Disease-Associated Glucocerebrosidases Show Mutation-Dependent Chemical Chaperoning Profiles. Chem. Biol. 12 1235.
166. M. Elleder, V. Bradova, F. Smid, et al. (1990) Cardiocyte Storage and Hypertrophy as a Sole Manifestation of Fabry’s Disease: Report on a Case Simulating Hypertrophic Non-Obstructive Cardiomyopathy. Virchows Arch. A Pathol. Anat. Histopathol. 417 449.
167. S. Nakao, C. Kodama, T. Takenaka, et al. (2003) Fabry Disease: Detection of Undiagnosed Hemodialysis Patients and Identification of a “Renal Variant” Phenotype. Kidney Int. 64 801.
168. S. Nakao, T. Takenaka, M. Maeda, et al. (1995) An Atypical Variant of Fabry’s Disease in Men with Left Ventricular Hypertrophy. N. Engl. J. Med. 333 288.
169. W. von Scheidt, C.M. Eng, T.F. Fitzmaurice, et al. (1991) An Atypical Variant of Fabry’s Disease with Manifestations Confined to the Myocardium. N. Engl. J. Med. 324 395.
170. P.D. Stenson, E.V. Ball, M. Mort, et al. (2003) Human Gene Mutation Database (HGMD): 2003 Update. Hum. Mutat. 21 577.
171. S. Garman and D. Garboczi (2002) Structural Basis of Fabry Disease. Mol. Genet. Metab. 77 3.
172. S.C. Garman and D.N. Garboczi (2004) The Molecular Defect Leading to Fabry Disease: Structure of Human Alpha-Galactosidase. J. Mol. Biol. 337 319.
173. F. Matsuzawa, S.I. Aikawa, H. Doi, et al. (2005) Fabry Disease: Correlation between Structural Changes in Alpha-Galactosidase, and Clinical and Biochemical Phenotypes. Hum. Genet. 117 317.
174. S. Dominissini, R. Cariati, M. Nevyjel, et al. (2004) Comparative In Vitro Expression Study of Four Fabry Disease Causing Mutations at Glutamine 279 of the Alpha-Galactosidase A Protein. Hum. Hered. 57 138.
175. M. Yasuda, J. Shabbeer, S.D. Benson, et al. (2003) Fabry Disease: Characterization of Alpha-Galactosidase A Double Mutations and the D313Y Plasma Enzyme Pseudodeficiency Allele. Hum. Mutat. 22 486.
176. T. Okumiya, S. Ishii, T. Takenaka, et al. (1995) Galactose Stabilizes Various Missense Mutants of Alpha-Galactosidase in Fabry Disease. Biochem. Biophys. Res. Commun. 214 1219.
177. G.H. Yam, C. Zuber and J. Roth (2005) A Synthetic Chaperone Corrects the Trafficking Defect and Disease Phenotype in a Protein Misfolding Disorder. FASEB J. 19 12.
178. S. Ishii, H. Yoshioka, K. Mannen, et al. (2004) Transgenic Mouse Expressing Human Mutant Alpha-Galactosidase A in an Endogenous Enzyme Deficient Background: A Biochemical Animal Model for Studying Active-Site Specific Chaperone Therapy for Fabry Disease. Biochim. Biophys. Acta 1690 250.
179. E. Beutler, G. Grabowski (2001) Gaucher Disease. C.R. Scriver, A.L. Beaudet, W.S. Sly, et al., (Eds) The Metabolic and Molecular Bases of Inherited Disease New York: McGraw-Hill 3635.
180. H. Dvir, M. Harel, A.A. McCarthy, et al. (2003) X-Ray Structure of Human Acid-Beta-Glucosidase, the Defective Enzyme in Gaucher Disease. EMBO Rep. 4 704.
181. A. Brautbar, D. Elstein, A. Abrahamov, et al. (2003) The 1604A (R496H) Mutation in Gaucher Disease: Genotype/Phenotype Correlation. Blood Cells Mol. Dis. 31 187.
182. P.D. Whitfield, P. Nelson, P.C. Sharp, et al. (2002) Correlation among Genotype, Phenotype, and Biochemical Markers in Gaucher Disease: Implications for the Prediction of Disease Severity. Mol. Genet. Metab. 75 46.
183. I. Ron and M. Horowitz (2005) ER Retention and Degradation as the Molecular Basis Underlying Gaucher Disease Heterogeneity. Hum. Mol. Genet. 14 2387.
184. Y. Suzuki, A. Oshima, E. Nanba (2001) β-Galactosidase Deficiency (β-Galactosidosis): GM1 Gangliosidosis and Morquio B Disease. C.R. Scriver, A.L. Beaudet, W.S. Sly, et al., (Eds) The Metabolic and Molecular Bases of Inherited Diseases New York: McGraw-Hill 3775.
185. R.A. Gravel, M.M. Kaback, R.L. Proia, et al. (2001) The GM2 Gangliosidoses. C.R. Scriver, A.L. Beaudet, W.S. Sly, et al., (Eds) The Metabolic and Molecular Bases of Inherited Diseases New York: McGraw-Hill 3827.
186. M. Kaback, J. Lim-Steele, D. Dabholkar, et al. (1993) Tay–Sachs Disease—Carrier Screening, Prenatal Diagnosis, and the Molecular Era: An International Perspective, 1970 to 1993. The International TSD Data Collection Network. JAMA 270 2307.
187. J.C. Sacchettini and J.W. Kelly (2002) Therapeutic Strategies for Human Amyloid Diseases. Nat. Rev. Drug Discov. 1 267.
188. S.M. Noorwez, R. Malhotra, J.H. McDowell, et al. (2004) Retinoids Assist the Cellular Folding of the Autosomal Dominant Retinitis Pigmentosa Opsin Mutant P23H. J. Biol. Chem. 279 16278.
189. J.P. Morello, A. Salahpour, A. Laperriere, et al. (2000) Pharmacological Chaperones Rescue Cell-Surface Expression and Function of Misfolded V2 Vasopressin Receptor Mutants. J. Clin. Invest. 105 887.
190. R.W. Carrell and D.A. Lomas (2002) Alpha1-Antitrypsin Deficiency—A Model for Conformational Diseases. N. Engl. J. Med. 346 45.
191. N. Gregersen, P. Bross, M.M. Jorgensen, et al. (2000) Defective Folding and Rapid Degradation of Mutant Proteins Is a Common Disease Mechanism in Genetic Disorders. J. Inherit. Metab. Dis. 23 441.
192. G. Kuznetsov and S.K. Nigam (1998) Folding of Secretory and Membrane Proteins. N. Engl. J. Med. 339 1688.
193. J.P. Morello, U.E. Petaja-Repo, D.G. Bichet, et al. (2000) Pharmacological Chaperones: A New Twist on Receptor Folding. Trends Pharmacol. Sci. 21 466.
194. W.J. Welch and C.R. Brown (1996) Influence of Molecular and Chemical Chaperones on Protein Folding. Cell Stress Chaperones 1 109.
195. S.R. Miranda, S. Erlich, V.L. Friedrich Jr., et al. (2000) Hematopoietic Stem Cell Gene Therapy Leads to Marked Visceral Organ Improvements and a Delayed Onset of Neurological Abnormalities in the Acid Sphingomyelinase Deficient Mouse Model of Niemann–Pick Disease. Gen. The. 7 1768.
196. http://www.fda.gov/ohrms/dockets/ac/cder03.html#endocrinologicmetabolicdrugs.
197. http://www.amicustherapeutics.com.
198. http://www.clinicaltrials.gov/ct/show/nct00214500?order=1.